Placebo controlled,randomised,crossover study of the efficacy of dipyridamole in the management of angina in patients with Coronary Slow Flow Phenomenon

Placebo controlled, randomised, crossover study of the efficacy of dipyridamole in reducing the number of angina episodes in patients with Coronary Slow Flow Phenomenon (CSFP)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12606000236594

Acronym

Nil

Enrollment

Registered

2006-06-14

Start date

2002-10-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

To assess if dipyridamole reduces the frequency of angina in patient with CSFP. Study pharmacist was the only person unblinded to study treatment. Blinding was achieved by using pre numbered study drug containers and by fax randomisation to study pharmacist who would then allocate the study drug to the patient who is also blinded

Interventions

Dipyridamole 200mgs orally twice daily for 10 weeks ie 5 weeks of each treatment blinded.After 5 weeks of treatment patients would cross over to opposite treatment.Patients and study staff(excluding study pharmacist) remain blinded to the study drug throughout the duration of the study.

Study design

Allocation

Randomised controlled trial

Intervention model

Crossover

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Coronary slow flow phenomenon. Frequent angina(> 3 episodes per week).

Exclusion criteria

Significant haemorrhagic risk.

Outcome results